Demonstration of Toxoplasma antigen containing complexes in active XXXX .

@entity1 @entity19 @entity3252 @entity7110
With an enzyme-linked immunosorbent assay antigen, specific @entity7110 ( @entity7110 ) were demonstrated in experimental and @entity1 @entity3252 . In experimentally infected @entity19 , @entity7110 became demonstrable as soon as antibodies appeared after fatal infection. When a nonvirulent strain of Toxoplasma was used @entity7110 remained detectable for several weeks. This period was characterized by clinically healthy animals with increasing antibody titers and by cysts growing in the brains of the animals, indicating a subacute stage of the toxoplasma infection. In the @entity1 sera, a surprisingly high percentage of @entity7110 was demonstrated. Both immunoglobulin G (IgG) and IgM were found in the @entity7110 ; however, IgG was seen in the majority. If the @entity1 were grouped according to other serological results, such as a combination with IgM antibodies, circulating antigens, or both, or a positive complement fixation test, increasingly more @entity7110 were observed. When sera were selected from @entity1 with clinical symptoms generally associated with @entity3252 , more @entity7110 were also again demonstrated. On the contrary, in healthy individuals (blood donors), @entity7110 were also regularly observed, suggesting that exacerbations of latent infections or reinfections may regularly occur without leading to clinical signs. In conclusion, we propose that the interpretation of a positive @entity7110 test requires great care but may provide useful information about the activity of a toxoplasma infection.
